Tulane University researchers have developed a new drug that is effective against non-severe cases of malaria, according to results from an FDA-supervised clinical trial published online in The Lancet Infectious Diseases.
The results are significant as public health experts have long warned that the parasite responsible for most malaria cases, Plasmodium falciparum, is developing resistance to widely used treatments. New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
“The potential long-term implications are bigger than one drug. The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well.”
Dr. Donald Krogstad
“The clinical trial results are extraordinarily encouraging,” said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine. “Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance. Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
The Latest on: Malaria
Scientists record breakthrough in HIV, malaria vaccine
on July 11, 2018 at 9:34 pm
Findings have shown that an experimental HIV-1 vaccine regimen is well-tolerated and generated comparable and robust immune responses against (Human Immunodeficiency Virus) HIV in healthy adults and r... […]
Tafenoquine May Prove Mettle in 'Radical Cure' for Malaria
on July 11, 2018 at 12:33 pm
Investigational drug tafenoquine (GlaxoSmithKline) seemed effective and generally well-tolerated in clinical trials designed to evaluate the therapy as part of a radical cure for Plasmodium vivax mala... […]
Fewer malaria nets, lower costs, more protection
on July 10, 2018 at 8:44 am
Insecticide-treated bed nets—a crucial part of malaria protection throughout sub-Saharan Africa and regions of Asia—have long been distributed to people who need them through mass campaigns conducted ... […]
Why some people test positive for malaria after successful anti-malarial treatment
on July 10, 2018 at 7:47 am
Treating patients with malaria first requires a confirmed diagnosis. It has recently come to light that not all diagnosis tests are equal, and some tests, including rapid diagnostic tests (RDTs), can ... […]
Certain antibodies against a carbohydrate could protect against malaria
on July 10, 2018 at 2:29 am
Certain type of antibodies against α-Gal- a carbohydrate expressed by many organisms including the malaria parasite- could protect against malaria, according to a new study led by ISGlobal, an institu... […]
Atomic imaging exposes how malaria invades our blood cells
on July 9, 2018 at 5:33 pm
New research reveals, at an atomic level, how a major form of malaria, P. vivax, invades our red blood cells. The mosquito-borne malaria parasite is an ancient killer, predating the emergence of human... […]
A breakthrough for malaria elimination starts in the Americas
on July 9, 2018 at 1:30 pm
The views expressed by contributors are their own and not the view of The Hill A new global push in the fight against malaria began last month when Paraguay became the first country in the Americas to ... […]
Certain antibodies against a sugar are associated with malaria protection
on July 9, 2018 at 11:08 am
Certain type of antibodies against alpha-Gal- a carbohydrate expressed by many organisms including the malaria parasite- could protect against malaria, according to a new study. The resultsindicate th... […]
In a Rare Success, Paraguay Conquers Malaria
on July 9, 2018 at 2:02 am
A malaria specialist in Las Claritas, Venezuela, analyzing blood samples of patients who showed symptoms of infection. While Paraguay has recently eliminated the disease, other countries in the Americ... […]
A promising new tool to measure antibodies against malaria
on July 4, 2018 at 2:58 am
A multipipette is used for handling multiple samples when performing quantitative suspension arrays. Credit: Pau Fabregat Antibodies against multiple Plasmodium falciparum proteins (or antigens) can b... […]
via Google News and Bing News